Kathy D. Miller, MD
Ballvé Lantero Professor of Oncology
Bio
Dr. Kathy Miller is a professor of oncology and medicine for IU School of Medicine Department of Medicine Hematology/Oncology Division.Â
Titles & Appointments
- Ballvé Lantero Professor of Oncology
- Professor of Medicine
- Program Leader - Breast
- Assistant Division Director - Research
-
Education1997 FEL Fellowship, Indiana University School of Medicine, Indianapolis, IN1994 RES Residency, Johns Hopkins School of Medicine, Baltimore, MD1991 MD Johns Hopkins University1986 BS University of Miami
-
Research
Breast Cancer
-
PublicationsAssociation Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112).
Fazeli S; Snyder BS; Gareen IF; Lehman CD; Khan SA; Romanoff J; Gatsonis CA; Corsetti RL; Rahbar H; Spell DW; Blankstein KB; Han LK; Sabol JL; Bumberry JR; Miller KD; Sparano JA; Comstock CE; Wagner LI; Carlos RC; JAMA network open 2022 May 2Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Ballinger TJ; Jiang G; Shen F; Miller KD; Sledge GW Jr; Schneider BP; Cancer 2022 Mar 14Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Mayer EL; Fesl C; Hlauschek D; Garcia-Estevez L; Burstein HJ; Zdenkowski N; Wette V; Miller KD; Balic M; Mayer IA; Cameron D; Winer EP; Ponce Lorenzo JJ; Lake D; Pristauz-Telsnigg G; Haddad TC; Shepherd L; Iwata H; Goetz M; Cardoso F; Traina TA; Sabanathan D; Breitenstein U; Ackerl K; Metzger Filho O; Zehetner K; Solomon K; El-Abed S; Theall KP; Lu DR; Dueck A; Gnant M; DeMichele A; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Jan 7Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.
Sparano JA; O'Neill A; Graham N; Northfelt DW; Dang CT; Wolff AC; Sledge GW; Miller KD; NPJ breast cancer 2022 Feb 8Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.
Rosenberg SM; O'Neill A; Sepucha K; Miller KD; Dang CT; Northfelt DW; Sledge GW; Schneider BP; Partridge AH; JAMA network open 2022 Feb 1Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women.
Connolly RM; Miller KD; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Dec 15Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Radovich M; Solzak JP; Wang CJ; Hancock BA; Badve S; Althouse SK; Bray SM; Storniolo AMV; Ballinger TJ; Schneider BP; Miller KD; Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Aug 2A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Adams S; Othus M; Patel SP; Miller KD; Chugh R; Schuetze SM; Chamberlin MD; Haley BJ; Storniolo AMV; Reddy MP; Anderson SA; Zimmerman CT; O'Dea AP; Mirshahidi HR; Ahnert JR; Brescia FJ; Hahn O; Raymond JM; Biggs DD; Connolly RM; Sharon E; Korde LA; Gray RJ; Mayerson E; Plets M; Blanke CD; Chae YK; Kurzrock R; Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Oct 29Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events.
Ip EH; Saldana S; Miller KD; Carlos RC; Gareen IF; Sparano JA; Graham N; Zhao F; Lee JW; O'Connell NS; Cella D; Peipert JD; Gray RJ; Wagner LI; Cancer 2021 Nov 2Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112).
Fazeli S; Snyder BS; Gareen IF; Lehman CD; Khan SA; Romanoff J; Gatsonis CA; Miller KD; Sparano JA; Comstock CE; Wagner LI; Carlos RC; JAMA network open 2021 Nov 1Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Dec 7BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Schneider BP; Jiang G; Ballinger TJ; Shen F; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Hancock BA; Kassem N; Helft P; O'Neil B; Storniolo AMV; Badve S; Miller KD; Radovich M; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Dec 15A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ; Annals of oncology : official journal of the European Society for Medical Oncology 2019 Sep 1Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM; Clinical breast cancer 2019 May 2Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Pulliam N; Tang J; Wang W; Fang F; Sood R; O'Hagan HM; Miller KD; Clarke R; Nephew KP; Cancers 2019 Jan 4Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.
Lehman CD; Gatsonis C; Romanoff J; Khan SA; Carlos R; Solin LJ; Badve S; McCaskill-Stevens W; Corsetti RL; Rahbar H; Spell DW; Blankstein KB; Han LK; Sabol JL; Bumberry JR; Gareen I; Snyder BS; Wagner LI; Miller KD; Sparano JA; Comstock C; 2019 Jan 17Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M; Breast cancer research : BCR 2019 Aug 5Dual TGFß/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast.
Prasad M; Kumar B; Bhat-Nakshatri P; Anjanappa M; Sandusky G; Miller KD; Storniolo AM; Nakshatri H; Molecular cancer research : MCR 2019 Apr 16Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Munster P; Krop IE; LoRusso P; Ma C; Siegel BA; Shields AF; Molnár I; Wickham TJ; Reynolds J; Campbell K; Hendriks BS; Adiwijaya BS; Geretti E; Moyo V; Miller KD; 2018 Oct 26Metastatic breast cancer patients' expectations and priorities for symptom improvement.
Tometich DB; Mosher CE; Hirsh AT; Rand KL; Johns SA; Matthias MS; Outcalt SD; Schneider BP; Mina L; Storniolo AMV; Newton EV; Miller KD; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2018 May 7Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer.
Denduluri N; Miller K; O'Regan RM; 2018 May 23Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).
Miller KD; O'Neill A; Gradishar W; Hobday TJ; Goldstein LJ; Mayer IA; Bloom S; Brufsky AM; Tevaarwerk AJ; Sparano JA; Le-Lindqwister NA; Hendricks CB; Northfelt DW; Dang CT; Sledge GW Jr; 2018 Jul 24Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Traina TA; Miller K; Yardley DA; Eakle J; Schwartzberg LS; O'Shaughnessy J; Gradishar W; Schmid P; Winer E; Kelly C; Nanda R; Gucalp A; Awada A; Garcia-Estevez L; Trudeau ME; Steinberg J; Uppal H; Tudor IC; Peterson A; Cortes J; 2018 Jan 26Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial.
Mosher CE; Secinti E; Li R; Hirsh AT; Bricker J; Miller KD; Schneider B; Storniolo AM; Mina L; Newton EV; Champion VL; Johns SA; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2018 Jan 12E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
Yeruva SLH; Zhao F; Miller KD; Tevaarwerk AJ; Wagner LI; Gray RJ; Sparano JA; Connolly RM; 2018 Jan 11Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sparano J; O'Neill A; Alpaugh K; Wolff AC; Northfelt DW; Dang CT; Sledge GW; Miller KD; 2018 Dec 1The implications of insurance status on presentation, surgical management, and mortality among nonmetastatic breast cancer patients in Indiana.
Obeng-Gyasi S; Timsina L; Miller KD; Ludwig KK; Fisher CS; Haggstrom DA; 2018 Aug 28Impact of primary breast cancer therapy on energetic capacity and body composition.
Ballinger TJ; Reddy A; Althouse SK; Nelson EM; Miller KD; Sledge JS; Breast cancer research and treatment 2018 Aug 22A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD; 2018 Aug 2An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP; 2018 Apr 3Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA; 2018 Apr 17A system for detecting high impact-low frequency mutations in primary tumors and metastases.
Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H; Oncogene 2017 Sep 11Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Vaz-Luis I; O'Neill A; Sepucha K; Miller KD; Baker E; Dang CT; Northfelt DW; Winer EP; Sledge GW; Schneider B; Partridge AH; Cancer 2017 Mar 21<sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
Lee H; Shields AF; Siegel BA; Miller KD; Krop I; Ma CX; LoRusso PM; Munster PN; Campbell K; Gaddy DF; Leonard SC; Geretti E; Blocker SJ; Kirpotin DB; Moyo V; Wickham TJ; Hendriks BS; Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Mar 15Questioning Our APHINITY for More.
Miller KD; The New England journal of medicine 2017 Jun 5Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
Partridge AH; Sepucha K; O'Neill A; Miller KD; Baker E; Dang CT; Northfelt DW; Sledge GW; Schneider BP; Breast cancer research and treatment 2017 Jun 23Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
Chen YH; Hancock BA; Solzak JP; Brinza D; Scafe C; Miller KD; Radovich M; NPJ breast cancer 2017 Jul 3Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.
Schneider BP; Shen F; Jiang G; O'Neill A; Radovich M; Li L; Gardner L; Lai D; Foroud T; Sparano JA; Sledge GW Jr; Miller KD; 2017 Aug 21Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African-Americans.
Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW Jr; Oncotarget 2016 Oct 9Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors.
Johns SA; Brown LF; Beck-Coon K; Talib TL; Monahan PO; Giesler RB; Tong Y; Wilhelm L; Carpenter JS; Von Ah D; Wagner CD; de Groot M; Schmidt K; Monceski D; Danh M; Alyea JM; Miller KD; Kroenke K; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016 May 17Role of RPL39 in Metaplastic Breast Cancer.
Dave B; Gonzalez DD; Liu ZB; Li X; Wong H; Granados S; Ezzedine NE; Sieglaff DH; Ensor JE; Miller KD; Radovich M; KarinaEtrovic A; Gross SS; Elemento O; Mills GB; Gilcrease MZ; Chang JC; Journal of the National Cancer Institute 2016 Dec 31Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.
Schneider BP; Shen F; Gardner L; Radovich M; Li L; Miller KD; Jiang G; Lai D; O'Neill A; Sparano JA; Davidson NE; Cameron D; Gradus-Pizlo I; Mastouri RA; Suter TM; Foroud T; Sledge GW Jr; Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Dec 19Are There Differences in Treatment and Survival Between Poor, Older Black and White Women with Breast Cancer?
Aggarwal H; Callahan CM; Miller KD; Tu W; Loehrer PJ Sr; Journal of the American Geriatrics Society 2015 Oct 12Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.
Schneider BP; Li L; Radovich M; Shen F; Miller KD; Flockhart DA; Jiang G; Vance G; Gardner L; Vatta M; Bai S; Lai D; Koller D; Zhao F; O'Neill A; Smith ML; Railey E; White C; Partridge A; Sparano J; Davidson NE; Foroud T; Sledge GW Jr; Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Jul 2TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.
Perkins SM; Bales C; Vladislav T; Althouse S; Miller KD; Sandusky G; Badve S; Nakshatri H; Breast cancer research and treatment 2015 Jul 10What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?
Esteva FJ; Miller KD; Teicher BA; American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 2015A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007.
Miller KD; Althouse SK; Nabell L; Rugo H; Carey L; Kimmick G; Jones DR; Merino MJ; Steeg PS; Breast cancer research and treatment 2014 Sep 26Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
O'Shaughnessy J; Schwartzberg L; Danso MA; Miller KD; Rugo HS; Neubauer M; Robert N; Hellerstedt B; Saleh M; Richards P; Specht JM; Yardley DA; Carlson RW; Finn RS; Charpentier E; Garcia-Ribas I; Winer EP; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Oct 27Comparison of younger and older breast cancer survivors and age-matched controls on specific and overall quality of life domains.
Champion VL; Wagner LI; Monahan PO; Daggy J; Smith L; Cohee A; Ziner KW; Haase JE; Miller KD; Pradhan K; Unverzagt FW; Cella D; Ansari B; Sledge GW Jr; Cancer 2014 May 28Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
Schneider BP; Li L; Shen F; Miller KD; Radovich M; O'Neill A; Gray RJ; Lane D; Flockhart DA; Jiang G; Wang Z; Lai D; Koller D; Pratt JH; Dang CT; Northfelt D; Perez EA; Shenkier T; Cobleigh M; Smith ML; Railey E; Partridge A; Gralow J; Sparano J; Davidson NE; Foroud T; Sledge GW; British journal of cancer 2014 Aug 12Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.
Miller KD; Diéras V; Harbeck N; Andre F; Mahtani RL; Gianni L; Albain KS; Crivellari D; Fang L; Michelson G; de Haas SL; Burris HA; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 14Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1.
Gao M; Wang M; Miller KD; Zheng QH; Bioorganic & medicinal chemistry letters 2013 Jun 6A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Mina LA; Yu M; Johnson C; Burkhardt C; Miller KD; Zon R; Investigational new drugs 2013 Jun 28Synthesis of radiolabeled protein disulfide isomerase (PDI) inhibitors as new potential PET agents for imaging of the enzyme PDI in neurological disorders and cancer.
Gao M; Yang Q; Wang M; Miller KD; Sledge GW; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2013 Jan 8Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
Schneider BP; Gray RJ; Radovich M; Shen F; Vance G; Li L; Jiang G; Miller KD; Gralow JR; Dickler MN; Cobleigh MA; Perez EA; Shenkier TN; Vang Nielsen K; Müller S; Thor A; Sledge GW Jr; Sparano JA; Davidson NE; Badve SS; Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jan 22Health-related quality of life of african american breast cancer survivors compared with healthy African American women.
Von Ah DM; Russell KM; Carpenter J; Monahan PO; Qianqian Z; Tallman E; Ziner KW; Storniolo AM; Miller KD; Giesler RB; Haase J; Otte J; Champion VL; Cancer nursing 2012 SepPharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment.
Schneider BP; Shen F; Miller KD; The Lancet. Oncology 2012 OctPredicting fear of breast cancer recurrence and self-efficacy in survivors by age at diagnosis.
Ziner KW; Sledge GW; Bell CJ; Johns S; Miller KD; Champion VL; Oncology nursing forum 2012 May 1A brief intervention to minimize psychosexual morbidity in dyads coping with breast cancer.
Decker CL; Pais S; Miller KD; Goulet R; Fifea BL; Oncology nursing forum 2012 Mar[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers.
Wang M; Gao M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2012 Jan 10Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-Raf(V600E) in cancers.
Wang M; Gao M; Miller KD; Zheng QH; Bioorganic & medicinal chemistry letters 2012 Dec 20Cognitive appraisals, coping and depressive symptoms in breast cancer patients.
Bigatti SM; Steiner JL; Miller KD; Stress and health : journal of the International Society for the Investigation of Stress 2012 Aug 10Simple synthesis of carbon-11-labeled chromen-4-one derivatives as new potential PET agents for imaging of DNA-dependent protein kinase (DNA-PK) in cancer.
Gao M; Wang M; Miller KD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2012 Apr 27Synthesis of 2-[11C]methoxy-3,17ß-O,O-bis(sulfamoyl)estradiol as a new potential PET agent for imaging of steroid sulfatase (STS) in cancers.
Wang M; Xu L; Gao M; Miller KD; Sledge GW; Zheng QH; Steroids 2012 Apr 19Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer.
Gao M; Wang M; Miller KD; Zheng QH; European journal of medicinal chemistry 2011 May 20Synthesis of [¹¹C]PBR06 and [¹8F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO).
Wang M; Gao M; Miller KD; Zheng QH; Steroids 2011 Jul 3[11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C.
Wang M; Xu L; Gao M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2011 Jan 31A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
Miller KD; O'Neill A; Perez EA; Seidman AD; Sledge GW; Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Aug 4Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging.
Gao M; Wang M; Miller KD; Zheng QH; Steroids 2011 Aug 17Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.
Gao M; Lola CM; Wang M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2011 Apr 20The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent.
Wang M; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Nuclear medicine and biology 2010 OctThe first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).
Wang M; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Bioorganic & medicinal chemistry letters 2010 Nov 11Facile synthesis of carbon-11-labeled cholesterol-based cationic lipids as new potential PET probes for imaging of gene delivery in cancer.
Gao M; Wang M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Steroids 2010 May 6Synthesis of carbon-11-labeled tricyclic necroptosis inhibitors as new potential PET agents for imaging of tumor necrosis factor alpha (TNF-alpha).
Gao M; Lola CM; Wang M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2010 May 5Depression in husbands of breast cancer patients: relationships to coping and social support.
Bigatti SM; Wagner CD; Lydon-Lam JR; Steiner JL; Miller KD; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010 Mar 10Synthesis of carbon-11-labeled casimiroin analogues as new potential PET agents for imaging of quinone reductase 2 and aromatase expression in breast cancer.
Wang M; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Steroids 2010 Jun 15Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD; Breast cancer research and treatment 2010 Jul 3Synthesis of carbon-11-labeled tariquidar derivatives as new PET agents for imaging of breast cancer resistance protein (ABCG2).
Wang M; Zheng DX; Luo MB; Gao M; Miller KD; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2010 Feb 13Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging.
Gao M; Wang M; Miller KD; Hutchins GD; Zheng QH; Bioorganic & medicinal chemistry 2010 Feb 10Synthesis of carbon-11-labeled 4-aryl-4H-chromens as new PET agents for imaging of apoptosis in cancer.
Gao M; Wang M; Miller KD; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2009 Sep 26Design and synthesis of carbon-11-labeled dual aromatase-steroid sulfatase inhibitors as new potential PET agents for imaging of aromatase and steroid sulfatase expression in breast cancer.
Wang M; Mickens J; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Steroids 2009 Jun 25A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Mina L; Krop I; Zon RT; Isakoff SJ; Schneider CJ; Yu M; Johnson C; Vaughn LG; Wang Y; Hristova-Kazmierski M; Shonukan OO; Sledge GW; Miller KD; Investigational new drugs 2009 Feb 13Synthesis of carbon-11 labeled celecoxib derivatives as new candidate PET radioligands for imaging of inflammation.
Gao M; Wang M; Miller KD; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2009 Aug 3The role of vascular endothelial growth factor genetic variability in cancer.
Schneider BP; Radovich M; Miller KD; Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Aug 25Redefining the target again: chemotherapeutics as vascular disrupting agents?
Gokmen-Polar Y; Miller KD; Cancer cell 2008 Sep 9Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP; Wang M; Radovich M; Sledge GW; Badve S; Thor A; Flockhart DA; Hancock B; Davidson N; Gralow J; Dickler M; Perez EA; Cobleigh M; Shenkier T; Edgerton S; Miller KD; ECOG 2100; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Oct 1Simple synthesis of carbon-11 labeled styryl dyes as new potential PET RNA-specific, living cell imaging probes.
Wang M; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; European journal of medicinal chemistry 2008 Mar 7Synthesis of new carbon-11 labeled naphthalene-sulfonamides for PET imaging of human CCR8.
Wang M; Cooley B; Gao M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2008 Mar 20Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.
Gao M; Wang M; Miller KD; Sledge GW; Zheng QH; European journal of medicinal chemistry 2008 Jan 11Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.
Ademuyiwa FO; Miller KD; Clinical breast cancer 2008 DecDevelopment of new targeted therapies for breast cancer.
Doyle DM; Miller KD; Cancer treatment and research 2008Development of new targeted therapies for breast cancer.
Doyle DM; Miller KD; Breast cancer (Tokyo, Japan) 2008Antiangiogenic agents in breast cancer.
Salter JT; Miller KD; Cancer investigation 2007 OctSynthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast cancer estrogen receptors.
Gao M; Wang M; Mock BH; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2007 Nov 19Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents.
Wang M; Gao M; Miller KD; Sledge GW; Zheng QH; Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2007 May 31Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study.
Shen C; Breen TE; Dobrolecki LE; Schmidt CM; Sledge GW; Miller KD; Hickey RJ; Cancer informatics 2007 Dec 11Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents.
Wang M; Gao M; Mock BH; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Bioorganic & medicinal chemistry 2006 Sep 8Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in cancers.
Gao M; Wang M; Miller KD; Sledge GW; Hutchins GD; Zheng QH; Bioorganic & medicinal chemistry letters 2006 Sep 6Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.
James J; Murry DJ; Treston AM; Storniolo AM; Sledge GW; Sidor C; Miller KD; Investigational new drugs 2006 Sep 13Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer.
Wang M; Lacy G; Gao M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2006 Oct 26Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue.
Mina L; Soule SE; Badve S; Baehner FL; Baker J; Cronin M; Watson D; Liu ML; Sledge GW Jr; Shak S; Miller KD; Breast cancer research and treatment 2006 Oct 13Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Shanmugam R; Jayaprakasan V; Gokmen-Polar Y; Kelich S; Miller KD; Yip-Schneider M; Cheng L; Bhat-Nakshatri P; Sledge GW Jr; Nakshatri H; Zheng QH; Miller MA; DeGrado T; Hutchins GD; Sweeney CJ; The Prostate 2006 Oct 1Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer.
Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS; Clinical cancer research : an official journal of the American Association for Cancer Research 2006 May 15Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
Wang JQ; Gao M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2006 May 11A physiologic imaging pilot study of breast cancer treated with AZD2171.
Miller KD; Miller M; Mehrotra S; Agarwal B; Mock BH; Zheng QH; Badve S; Hutchins GD; Sledge GW Jr; Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Jan 1Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.
Gao M; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2005 Sep 1Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase.
Wang JQ; Miller KD; Sledge GW; Zheng QH; Bioorganic & medicinal chemistry letters 2005 Oct 1A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.
Miller KD; Trigo JM; Wheeler C; Barge A; Rowbottom J; Sledge G; Baselga J; Clinical cancer research : an official journal of the American Association for Cancer Research 2005 May 1Angiogenesis of breast cancer.
Schneider BP; Miller KD; 2005 Mar 10 -
Clinical Interests
Breast Cancer
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.